Axa
MRSN

Axa’s Mersana Therapeutics MRSN Stock Holding History

Axa’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,164
Closed -$610K – 1152
2022
Q4 		$610K Sell
4,164
-5,148
-55% -$870K ﹤0.01% 965
2022
Q3 		$1.57M Buy
9,312
+8,880
+2,056% +$1.44M 0.01% 791
2022
Q2 		$49.9K Hold
432
– – ﹤0.01% 1101
2022
Q1 		$43.1K Sell
432
-5,488
-93% -$641K ﹤0.01% 1178
2021
Q4 		$921K Buy
+5,920
New +$1.15M ﹤0.01% 957
2021
Q1 		– Sell
-8,202
Closed -$5.46M – 1289
2020
Q4 		$5.46M Buy
8,202
+331
+4% +$184K 0.02% 671
2020
Q3 		$3.66M Sell
7,871
-2,477
-24% -$1.25M 0.01% 706
2020
Q2 		$6.05M Sell
10,348
-3,991
-28% -$1.36M 0.02% 556
2020
Q1 		$2.09M Buy
+14,339
New +$2.51M 0.01% 725

Other funds holding MRSN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Axa's MRSN Position: Q1 2023 in Review

Axa sold out of Mersana Therapeutics (MRSN) in Q1 2023, closing a stake of 4,164 shares — an estimated $610K sold.

Axa first reported a position in MRSN in Q1 2020 and held it in 9 quarters. The position peaked at $6.05M in Q2 2020. 157 funds tracked by Wall St. Rank hold MRSN as of Q1 2023.

  • Axa reported no remaining Mersana Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Axa sold 4,164 Mersana Therapeutics shares in Q1 2023, an estimated $610K.
  • Axa first reported a position in Mersana Therapeutics in Q1 2020 and held it in 9 quarters.
  • Axa's Mersana Therapeutics position peaked at $6.05M in Q2 2020.
  • 157 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2023.

Based on Axa's 13F filing for Q1 2023, filed 15 May 2023.